These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25162656)
1. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. Sugarman MA; Loree AM; Baltes BB; Grekin ER; Kirsch I PLoS One; 2014; 9(8):e106337. PubMed ID: 25162656 [TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354 [TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH; J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366 [TBL] [Abstract][Full Text] [Related]
4. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Rickels K; Zaninelli R; McCafferty J; Bellew K; Iyengar M; Sheehan D Am J Psychiatry; 2003 Apr; 160(4):749-56. PubMed ID: 12668365 [TBL] [Abstract][Full Text] [Related]
5. Remission rates in patients with anxiety disorders treated with paroxetine. Ballenger JC J Clin Psychiatry; 2004 Dec; 65(12):1696-707. PubMed ID: 15641876 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
7. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626 [TBL] [Abstract][Full Text] [Related]
8. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817 [TBL] [Abstract][Full Text] [Related]
9. Spotlight on paroxetine in psychiatric disorders in adults. Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788 [TBL] [Abstract][Full Text] [Related]
10. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830 [TBL] [Abstract][Full Text] [Related]
11. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. Noma H; Furukawa TA; Maruo K; Imai H; Shinohara K; Tanaka S; Ikeda K; Yamawaki S; Cipriani A J Affect Disord; 2019 May; 250():419-424. PubMed ID: 30878654 [TBL] [Abstract][Full Text] [Related]
12. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E BMJ; 2015 Sep; 351():h4320. PubMed ID: 26376805 [TBL] [Abstract][Full Text] [Related]
13. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Moonen AJ; Wijers A; Leentjens AF; Christine CW; Factor SA; Juncos J; Lyness JM; Marsh L; Panisset M; Pfeiffer R; Rottenberg D; Serrano Ramos C; Shulman L; Singer C; Slevin J; McDonald W; Auinger P; Richard IH Parkinsonism Relat Disord; 2014 Jun; 20(6):644-6. PubMed ID: 24679737 [TBL] [Abstract][Full Text] [Related]
14. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Liebowitz MR; Stein MB; Tancer M; Carpenter D; Oakes R; Pitts CD J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629 [TBL] [Abstract][Full Text] [Related]
17. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Bakker A; van Dyck R; Spinhoven P; van Balkom AJ J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Sheehan DV; Burnham DB; Iyengar MK; Perera P; J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886 [TBL] [Abstract][Full Text] [Related]
19. Surprising results in the study of paroxetine for generalized anxiety disorder. Ballas CA J Clin Psychiatry; 2002 Jun; 63(6):536; author reply 536-7. PubMed ID: 12088169 [No Abstract] [Full Text] [Related]
20. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Mazeh D; Shahal B; Aviv A; Zemishlani H; Barak Y Int Clin Psychopharmacol; 2007 Nov; 22(6):371-5. PubMed ID: 17917556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]